Wipro Limited Announces Results for the Quarter ended June 30, 2022 under IFRS
IT Services delivers constant currency growth in revenues at 17.2% in YoY CC NEW YORK…
Month: July 2022
United States Aerospace & Defense Operations in the Information Environment 2022: Future Growth Potential of Informational Power in Military Applications – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “US Aerospace & Defense Operations in the Information Environment Growth Opportunities” report has…
New Ponemon Institute Study Finds 60% of IT and Security Leaders are not Confident in Their Ability to Secure Access to Cloud Environments
Global survey reveals Zero Trust security can mitigate distributed infrastructure risks and help organizations accelerate…
Wellsheet Recognized as a Sample Vendor in Smart EHR UI in a Gartner Report
Smart EHR UI Critical as Healthcare Burnout and Turnover Reach Record Levels, Jeopardizing Patient Care…
One Source Unveils Recommendations for North Carolina Companies to Navigate the Complexities of Cybersecurity Insurance
Local and regional businesses seek financial security amid rise in ransomware and other cyberattacks GREENVILLE,…
Recession May Be Looming in Second Half, Say Strategists Surveyed by Natixis Investment Managers
Results of the Natixis Center for Investor Insight mid-year survey of 34 experts show that…
Bright Data 2022 Impact Report Highlights Progress Across ESG Initiatives and Growth of The Bright Initiative
The Bright Initiative now partners with over 600 leading organizations, including more than 200 academic institutions…
G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX),…
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in…
PointCross Releases eDataValidator for SDTM, ADaM, SEND, and Define.XML Conformance to Prevailing FDA, CDISC, and PMDA Rules
Integrated QC dashboard and unlimited validation cycles for interim and final datasets creates industry’s most…
FDA Approves QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17
CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) — VIVUS LLC today announced that the U.S….
Secure Transfusion Solutions Announces Company Name Change and Opening of its Third Trusting Heart Blood Center in Beaverton, Oregon
Formerly recognized as Secure Transfusion Services, the company will now be known as “Secure Transfusion…
Trusting Heart Blood Center Announces the Opening of its Third Platelet Donation Center in Beaverton, Oregon
BEAVERTON, Ore., July 20, 2022 (GLOBE NEWSWIRE) — Trusting Heart Blood Center (THBC) announces the…
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher…
Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced…
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
Professor C.H.J. van Eijck, MD, PhD Professor C.H.J. van Eijck, MD, PhD Ampligen® (rintatolimod) has…
Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead
BURNABY, British Columbia, July 20, 2022 (GLOBE NEWSWIRE) — Qu Biologics Inc., a private clinical…
Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales…
Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales…
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France
— Reimbursed early access program allows for patients in France to receive setmelanotide for treatment…